Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2022, Propel Bio Partners is a venture capital firm based in Los Angeles and Seattle, dedicated to advancing human health through investments in life science companies. The firm was established to support entrepreneurs developing groundbreaking therapies and technologies that can significantly impact human health. Propel Bio Partners has a target fund size of $150 million, which it aims to deploy in the biotech and healthcare sectors.
The firm currently operates with a team of 10 professionals, including General Partners, Analysts, and Advisors, who bring diverse expertise in finance, investment, and medical advisory roles. Propel Bio Partners is committed to building ecosystems that empower founders, providing not only financial backing but also access to a network of medical experts and operational advisors. This approach is designed to help portfolio companies navigate the complexities of the life sciences landscape.
Notable milestones include the addition of Laurie Heilmann as a Venture Partner in January 2026, enhancing the firm's strategic leadership. Propel Bio Partners is also listed on the Medical Technology Enterprise Consortium of Southern California (MTEC-SC) investor directory, indicating its active engagement in the life sciences investment community.
Propel Bio Partners invests primarily in life science companies, with a strong emphasis on biotech and healthcare sectors. The firm seeks to support the development of disruptive technologies and therapies that can enhance human health. Its investment strategy is characterized by a commitment to advancing scientific innovations through financial investment and operational support.
The firm typically targets early-stage investments, focusing on companies that are developing groundbreaking therapies and technologies. Propel Bio Partners leverages its expertise in finance and investment to help these companies achieve their vision. The firm looks for founders who are passionate about their projects and possess a clear understanding of the market and their technology's potential impact.
Deal structures often include a combination of equity investments and strategic partnerships, allowing Propel Bio Partners to align closely with the goals of its portfolio companies. The firm is particularly interested in building long-term relationships with entrepreneurs, providing them with the resources and support needed to navigate the complexities of the life sciences sector.
Richard Kayne, MBA - General Partner. Richard is a co-founder of Propel Bio Partners and has a background in investment, having founded Kayne Anderson Capital Advisors, a major institutional investment firm.
Leen Kawas, PhD - Managing General Partner. Leen is a co-founder and a biotech entrepreneur, previously serving as the CEO of Athira Pharma, where she led significant advancements in the biotech field.
Xue Hua, PhD - Managing Partner. Xue brings extensive experience in life sciences and investment, contributing to the firm's strategic direction.
Jim Harding, CPA, CMA - Finance. Jim oversees financial operations and brings a wealth of experience in financial management within the investment sector.
Erik Gonzalez-Leon, PhD - Analyst. Erik supports investment analysis and research, focusing on emerging trends in life sciences.
Sam Berry, PhD - Analyst. Sam contributes to the firm's research efforts, analyzing potential investment opportunities in the biotech sector.
Joyce Jiang, MPH, PhD - Analyst. Joyce specializes in health policy and research, providing insights into the healthcare landscape.
Safiya Alavi - Associate, Data Science and Research. Safiya focuses on data analysis and research support for the firm's investment decisions.
Armaan Hirani - Intern. Armaan assists with various research and operational tasks within the firm.
Ron Farkas, MD, PhD - Senior Advisor. Ron provides medical expertise and guidance to portfolio companies.
Sylvia McBrinn, MBA - Senior Advisor. Sylvia offers insights into business strategy and commercialization.
Mike Gibbs - Senior Advisor. Mike brings experience in regulatory affairs and clinical development.
Ronald Lee Krall, MD - Senior Advisor. Ronald provides clinical insights and guidance to the firm's portfolio companies.
Suzanne Hendrix, PhD - Advisor. Suzanne specializes in scientific research and development.
Richard Sudek, PhD - Advisor. Richard offers expertise in technology commercialization.
Carol Criner - Advisor. Carol provides strategic insights into business development.
Laurie Heilmann - Venture Partner. Laurie joined in January 2026 and brings extensive experience in healthcare technology and life sciences.
To pitch Propel Bio Partners, startups should visit their website at propelbio.com. The firm prefers detailed pitch decks that include information about the technology, market potential, and the founding team's background. A clear articulation of the problem being solved and the solution's unique value proposition is crucial.
Response times can vary, but founders should expect a thorough review process. Warm introductions are encouraged, as they can facilitate a more favorable reception of the pitch.
In January 2026, Propel Bio Partners announced the addition of Laurie Heilmann as a Venture Partner, enhancing the firm's strategic leadership. This move is expected to strengthen the firm's focus on supporting life science companies.
Propel Bio Partners commenced operations in 2022, with a target fund size of $150 million aimed at investing in life science companies. The firm has been actively building its team and establishing its presence in the investment community.
Additionally, Propel Bio Partners is listed on the Medical Technology Enterprise Consortium of Southern California (MTEC-SC) investor directory, indicating its engagement with the life sciences investment ecosystem.
What are Propel Bio Partners' investment criteria?
Propel Bio Partners focuses on investing in life science companies, particularly in the biotech and healthcare sectors. The firm seeks to support the development of disruptive technologies and therapies that can significantly impact human health. They look for early-stage companies with strong founding teams and innovative solutions.
How can startups apply or pitch to Propel Bio Partners?
Startups interested in pitching to Propel Bio Partners can do so through their website at propelbio.com. It is recommended to include a detailed overview of the technology, market potential, and the founding team's background in the pitch deck.
What makes Propel Bio Partners different from other venture capital firms?
Propel Bio Partners differentiates itself by providing not only financial investment but also access to a robust ecosystem of medical experts and operational advisors. This support helps portfolio companies navigate the complexities of the life sciences landscape effectively.
What is the geographic scope of Propel Bio Partners' investments?
The firm primarily invests in the United States, focusing on life science companies that are developing innovative therapies and technologies.
What is the typical check size for investments made by Propel Bio Partners?
While specific check sizes have not been disclosed, Propel Bio Partners is targeting a fund size of $150 million, indicating a capacity for significant investments in promising life science startups.
What kind of post-investment involvement does Propel Bio Partners have?
Propel Bio Partners is committed to actively supporting its portfolio companies through access to a network of medical experts and operational advisors. This involvement is designed to help companies achieve their vision and navigate challenges in the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.